CATAPULT SPORTS LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT

CAT - CATAPULT SPORTS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 0.55
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$6.60

03 Nov
2025

-0.120

OPEN

$6.65

-1.79%

HIGH

$6.74

773,892

LOW

$6.57

TARGET
$7.967 20.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 3.3 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920212022202320242025
EPS Basic xxxxxxxxxxxxxxx-5.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx178.7 M
Book Value Per Share xxxxxxxxxxxxxxx49.9
Net Operating Cash Flow xxxxxxxxxxxxxxx56.1 M
Net Profit Margin xxxxxxxxxxxxxxx-7.51 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-10.64 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.17 %
Return on Assets xxxxxxxxxxxxxxx-5.18 %
Return on Equity xxxxxxxxxxxxxxx-10.64 %
Return on Total Capital xxxxxxxxxxxxxxx-8.47 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx36.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx13 M
Total Debt xxxxxxxxxxxxxxx16 M
Goodwill - Gross xxxxxxxxxxxxxxx82 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx6.93

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920212022202320242025
Capex xxxxxxxxxxxxxxx45.8 M
Capex % of Sales xxxxxxxxxxxxxxx25.62 %
Cost of Goods Sold xxxxxxxxxxxxxxx162 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx29 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

15/10/2025

3

Hold

$7.50

13.64%

Catapult International announced the acquisition of Impect, provided a trading update and published preliminary 1H26 results.

Bell Potter notes the preliminary 1H26 results were broadly in line with its forecasts, with the annual contract value of US$115.3-115.6m coming close to its US$115.2m estimate. The company reiterated its FY26 outlook.

Following the update and after factoring in the Impect acquisition, the broker upgraded FY26 revenue forecast by 3% and FY27 by 7%.

Hold. Target rises to $7.50 from $6.00, up 25% on roll-forward and a higher valuation multiple to reflect Impect's value.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.58 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.87 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

11/06/2025

1

Buy

$6.20

-6.06%

Catapult International announced the -US$18m acquisition of Perch, a Boston-based sports technology company which offers off-field, AI-integrated athlete monitoring solutions, Canaccord Genuity explains.

The deal will be funded via US$3m cash on hand and a US$15m equity issue in four tranches, with a US$10m earn-out payable to Perch shareholders.

The analyst notes Perch's technology was developed originally at MIT, combining a 3D camera with proprietary AI that tracks athletes in the weight room to offer insights for personalised training programs.

The acquisition is viewed as strategically sound, with Perch's customers (American football) interfacing with Catapult's client base at over 4,600 teams across over 40 sports in 100 countries.

Buy rating is retained and target price moves to $6.20 from $5.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.47 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 4.05 cents.
Access Extra Coverage Research History >

CAT STOCK CHART

FNArena News on CAT

1
Rudi’s View: Eagers Automotive, Catapult, Fineos, Pro Medicus, Woolworths & More

Oct 30 2025 - Rudi's View
2
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
3
In Brief: Novonix, Catapult & Online Retailing

Jun 13 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Jun 11, 2025

Jun 11 2025 - Daily Market Reports
5
Next Week At A Glance – 9-13 Jun 2025

Jun 06 2025 - Weekly Reports

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia